Biogen Alzheimer’s Drug Hits Delays Caused by Data, Covid-19

(Bloomberg) -- Biogen Inc. said it now plans to submit a closely watched experimental Alzheimer’s drug for U.S. approval in the third quarter, after data-processing challenges and a coronavirus out...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.